UNLIMITED TURBO SHORT - MODERNA | Market Closed - Borsa Italiana 04:04:59 2024-07-12 pm EDT | ||
| 7.04 EUR | +1.29% |
|
| Current month | -8.09% | ||
| 1 month | +46.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 7.04 | +1.29% |
| 24-07-11 | 6.95 | -6.96% |
| 24-07-10 | 7.47 | -1.71% |
| 24-07-09 | 7.6 | +0.53% |
| 24-07-08 | 7.56 | +2.58% |
Real-time Borsa Italiana
Last update July 12, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P23825 | |
| ISIN | NLBNPIT23825 |
| Date issued | 2024-05-24 |
| Strike | 188.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.84 € |
|---|---|
| Lowest since issue | 2.69 € |
| Spread | 0.05 € |
| Spread % | 0.71% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.8
USD
Average target price
145.9
USD
Spread / Average Target
+18.79%
- Stock Market
- Certificates
- P23825 Certificat
